About Leap Therapeutics
Leap Therapeutics is a company based in Cambridge (United States) founded in 2011. It operates as a HealthTech. Leap Therapeutics has raised $24.68 million across 7 funding rounds from investors including BeiGene, Perceptive Advisors and Healthcare Ventures. The company has 52 employees as of December 31, 2024. Leap Therapeutics has completed 1 acquisition, including Macrocure. Leap Therapeutics offers products and services including Sirexatamab (DKN-01), FL-301, and FL-501. Leap Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 52 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Leap Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$67.56 M (USD)17.02as on Dec 31, 2024
-
EBITDA
-$70.05 M (USD)19.12as on Dec 31, 2024
-
Total Equity Funding
$24.68 M (USD)
in 7 rounds
-
Latest Funding Round
$58.9 M (USD), Post-IPO
Oct 06, 2025
-
Investors
BeiGene
& 3 more
-
Employee Count
52
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Leap Therapeutics
Leap Therapeutics is a publicly listed company on the NASDAQ with ticker symbol LPTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Leap Therapeutics
Leap Therapeutics offers a comprehensive portfolio of products and services, including Sirexatamab (DKN-01), FL-301, and FL-501.
Targeted therapy developed for DKK1-expressing cancer tumors.
Therapy developed for gastric and pancreatic cancer patients.
Preclinical therapy targeting GDF-15 protein for cancer.
People of Leap Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
5 people
Finance and Accounting
3 people
Product Management Team
3 people
Chairman Team
1 people
Software Development Team
1 people
Sales and Marketing
1 people
Data Analysis and Operations Team
1 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Leap Therapeutics
Leap Therapeutics has successfully raised a total of $24.68M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $58.9 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Leap Therapeutics
Leap Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include BeiGene, Perceptive Advisors and Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Winklevoss brothers' family office.
|
Locked | Locked | Locked |
Investor details for Leap Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Leap Therapeutics
Leap Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Macrocure.
Investment portfolio details for Leap Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell therapies for wound care are developed and commercialized.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Leap Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Leap Therapeutics
Detailed financials for Leap Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Leap Therapeutics Comparisons
Peer comparison for Leap Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Leap Therapeutics
Leap Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Leap Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Leap Therapeutics
Complete news archive for Leap Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Leap Therapeutics
Leap Therapeutics was founded in 2011.
Leap Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Leap Therapeutics is a funded company, having raised a total of $24.68M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Leap Therapeutics is 52.
Leap Therapeutics, Inc. is focused on the development of targeted and immuno-oncology therapeutics. The companys primary candidate, Sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. Additional programs include FL-301 for gastric and pancreatic cancer, and FL-501 targeting GDF-15 in preclinical stages. Solutions are aimed at addressing unmet needs in oncology through innovative therapies and combinations across multiple cancer types.
Leap Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Leap Therapeutics offers Sirexatamab (DKN-01), FL-301, and FL-501.
Yes, Leap Therapeutics is publicly traded on NASDAQ under the ticker symbol LPTX.
Leap Therapeutics has made 1 acquisition, including Macrocure.
Leap Therapeutics has 4 investors. Key investors include BeiGene, Perceptive Advisors, Healthcare Ventures, and Winklevoss Capital.
The ticker symbol of Leap Therapeutics is LPTX on NASDAQ.